Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline Review, H1 2015

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline Review, H1 2015', provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 10

Therapeutics Development 11

Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Overview 11

Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Comparative Analysis 12

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Therapeutics under Development by Companies 13

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Therapeutics under Investigation by Universities/Institutes 18

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Unknown Stage Products 24

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Products under Development by Companies 25

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Products under Investigation by Universities/Institutes 29

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Companies Involved in Therapeutics Development 31

AbbVie Inc. 31

Aprea AB 32

arGEN-X BV 33

Ariad Pharmaceuticals, Inc. 34

Array BioPharma Inc. 35

Astex Pharmaceuticals, Inc. 36

Bio-Path Holdings, Inc. 37

Biogenomics Limited 38

BioLineRx, Ltd. 39

Boston Biomedical, Inc. 40

Bristol-Myers Squibb Company 41

Cantargia AB 42

Celgene Corporation 43

Constellation Pharmaceuticals, Inc. 44

Daiichi Sankyo Company, Limited 45

Deciphera Pharmaceuticals, LLC 46

Eisai Co., Ltd. 47

EpiZyme, Inc. 48

Galena Biopharma, Inc. 49

Gamida Cell Ltd. 50

Hybrigenics S.A. 51

Ilyang Pharmaceutical Co., Ltd 52

Incyte Corporation 53

Jiangsu Hansoh Pharmaceutical Co., Ltd. 54

Jiangsu Hengrui Medicine Co., Ltd. 55

Juno Therapeutics Inc. 56

JW Pharmaceutical Corporation 57

KaloBios Pharmaceuticals, Inc. 58

Karyopharm Therapeutics, Inc. 59

Lixte Biotechnology Holdings, Inc. 60

Mirna Therapeutics, Inc. 61

Natco Pharma Limited 62

Novartis AG 63

Onconova Therapeutics, Inc. 64

Ono Pharmaceutical Co., Ltd. 65

OriBase Pharma 66

Otsuka Holdings Co., Ltd. 67

Pfizer Inc. 68

Pharma Mar, S.A. 69

PharmaEssentia Corporation 70

Selvita SA 71

Shenogen Pharma Group Ltd. 72

Stemline Therapeutics, Inc. 73

Sun Pharma Advanced Research Company Ltd. 74

Synta Pharmaceuticals Corp. 75

Threshold Pharmaceuticals, Inc. 76

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Therapeutics Assessment 77

Assessment by Monotherapy Products 77

Assessment by Target 78

Assessment by Mechanism of Action 82

Assessment by Route of Administration 85

Assessment by Molecule Type 87

Drug Profiles 89

ABL-001-Drug Profile 89

AIC-47-Drug Profile 90

anagrelide hydrochloride CR-Drug Profile 91

APR-246-Drug Profile 92

ARGX-110-Drug Profile 93

azacitidine-Drug Profile 96

BC-2059-Drug Profile 100

binimetinib-Drug Profile 102

BL-8040-Drug Profile 107

BMS-833923-Drug Profile 109

bosutinib-Drug Profile 111

BP-100101-Drug Profile 113

CAN-04-Drug Profile 115

Cell Therapy to Target GM-CSF for Oncology-Drug Profile 117

Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies-Drug Profile 119

CPI-0610-Drug Profile 120

CWP-291-Drug Profile 121

D-12PGJ3-Drug Profile 123

D-824-Drug Profile 124

danusertib-Drug Profile 125

Dendritic Cell Therapy for Hematological Malignancies-Drug Profile 127

Dendritic Cell Therapy for Oncology-Drug Profile 128

Dendritic Cell Therapy for Oncology and Infectious Disease-Drug Profile 129

Dendritic Cell Therapy to Target WT1 for Oncology-Drug Profile 130

DS-3032-Drug Profile 131

E-6201-Drug Profile 132

EPZ-5676-Drug Profile 134

erismodegib-Drug Profile 136

ES-3000-Drug Profile 139

ETC-027-Drug Profile 140

ETC-219-Drug Profile 141

evofosfamide-Drug Profile 142

flumatinib mesylate-Drug Profile 150

ganetespib-Drug Profile 151

Gene Therapy for Acute Myelocytic Leukemia and Chronic Myelocytic Leukemia-Drug Profile 155

guadecitabine-Drug Profile 156

HHGV-678-Drug Profile 159

ilorasertib-Drug Profile 160

inecalcitol-Drug Profile 162

inotuzumab ozogamicin-Drug Profile 164

interferon alfa-2a (recombinant)-Drug Profile 166

interferon alfa-2b-Drug Profile 167

interferon alfa-2b (recombinant)-Drug Profile 168

ipilimumab-Drug Profile 169

JTCR-016-Drug Profile 173

KB-004-Drug Profile 174

LB-100-Drug Profile 176

lurbinectedin-Drug Profile 178

MJ-05-Drug Profile 181

MRX-102-Drug Profile 182

MRX-34-Drug Profile 184

napabucasin-Drug Profile 186

nivolumab-Drug Profile 189

NOV-120501-Drug Profile 195

NRCAN-019-Drug Profile 196

OPB-51602-Drug Profile 198

ORB-0001-Drug Profile 200

PF-114-Drug Profile 201

ponatinib hydrochloride-Drug Profile 202

PRI-724-Drug Profile 204

radotinib-Drug Profile 206

rebastinib tosylate-Drug Profile 208

rigosertib sodium-Drug Profile 209

ropeginterferon ALFA-2B-Drug Profile 214

ruxolitinib phosphate-Drug Profile 216

SEL-24B489-Drug Profile 221

selinexor-Drug Profile 222

SL-401-Drug Profile 227

SL-501-Drug Profile 229

Small Molecule to Inhibit ADAR1 for Chronic Myeloid Leukemia-Drug Profile 230

Small Molecules to Inhibit Abl Tyrosine Kinase for CML-Drug Profile 231

Small Molecules to Inhibit BCR-ABL for CML-Drug Profile 232

Small Molecules to Inhibit Bcr-Abl for CML and Pancreatic Cancer-Drug Profile 233

Small Molecules to Inhibit BRCA2/Rad51 Interaction for Cancer-Drug Profile 234

SNG-1153-Drug Profile 235

SNG-162-Drug Profile 236

StemEx-Drug Profile 237

SUNK-706-Drug Profile 238

TR-120-Drug Profile 239

trametinib dimethyl sulfoxide-Drug Profile 240

Vaccine to Target Bcr-Abl Tyrosine Kinase for Chronic Myeloid Leukemia-Drug Profile 243

Vaccine to Target Wilms Tumor Protein for Oncology-Drug Profile 244

Vaccine to Target WT1 for CML and AML-Drug Profile 245

Vaccine to Target WT1 for Oncology-Drug Profile 246

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Recent Pipeline Updates 247

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Dormant Projects 365

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Discontinued Products 370

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Product Development Milestones 372

Featured News & Press Releases 372

Appendix 384

Methodology 384

Coverage 384

Secondary Research 384

Primary Research 384

Expert Panel Validation 384

Contact Us 384

Disclaimer 385

List of Tables

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2015 17

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 26

Comparative Analysis by Late Stage Development, H1 2015 27

Comparative Analysis by Clinical Stage Development, H1 2015 28

Comparative Analysis by Early Stage Development, H1 2015 29

Comparative Analysis by Unknown Stage Development, H1 2015 30

Products under Development by Companies, H1 2015 31

Products under Development by Companies, H1 2015 (Contd..1) 32

Products under Development by Companies, H1 2015 (Contd..2) 33

Products under Development by Companies, H1 2015 (Contd..3) 34

Products under Investigation by Universities/Institutes, H1 2015 35

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 36

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by AbbVie Inc., H1 2015 37

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Aprea AB, H1 2015 38

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by arGEN-X BV, H1 2015 39

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 40

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Array BioPharma Inc., H1 2015 41

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 42

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Bio-Path Holdings, Inc., H1 2015 43

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Biogenomics Limited, H1 2015 44

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by BioLineRx, Ltd., H1 2015 45

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Boston Biomedical, Inc., H1 2015 46

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Bristol-Myers Squibb Company, H1 2015 47

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Cantargia AB, H1 2015 48

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Celgene Corporation, H1 2015 49

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 50

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 51

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 52

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Eisai Co., Ltd., H1 2015 53

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by EpiZyme, Inc., H1 2015 54

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Galena Biopharma, Inc., H1 2015 55

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Gamida Cell Ltd., H1 2015 56

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Hybrigenics S.A., H1 2015 57

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Ilyang Pharmaceutical Co., Ltd, H1 2015 58

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Incyte Corporation, H1 2015 59

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 60

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 61

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Juno Therapeutics Inc., H1 2015 62

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by JW Pharmaceutical Corporation, H1 2015 63

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 64

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 65

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 66

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Mirna Therapeutics, Inc., H1 2015 67

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Natco Pharma Limited, H1 2015 68

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Novartis AG, H1 2015 69

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Onconova Therapeutics, Inc., H1 2015 70

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 71

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by OriBase Pharma, H1 2015 72

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 73

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Pfizer Inc., H1 2015 74

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Pharma Mar, S.A., H1 2015 75

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by PharmaEssentia Corporation, H1 2015 76

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Selvita SA, H1 2015 77

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Shenogen Pharma Group Ltd., H1 2015 78

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Stemline Therapeutics, Inc., H1 2015 79

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 80

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Synta Pharmaceuticals Corp., H1 2015 81

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 82

Assessment by Monotherapy Products, H1 2015 83

Number of Products by Stage and Target, H1 2015 85

Number of Products by Stage and Mechanism of Action, H1 2015 89

Number of Products by Stage and Route of Administration, H1 2015 92

Number of Products by Stage and Molecule Type, H1 2015 94

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics-Recent Pipeline Updates, H1 2015 253

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Dormant Projects, H1 2015 371

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Dormant Projects (Contd..1), H1 2015 372

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Dormant Projects (Contd..2), H1 2015 373

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Dormant Projects (Contd..3), H1 2015 374

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Dormant Projects (Contd..4), H1 2015 375

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Discontinued Products, H1 2015 376

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Discontinued Products (Contd..1), H1 2015 377

List of Figures

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2015 17

Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 19

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 28

Comparative Analysis by Early Stage Products, H1 2015 29

Assessment by Monotherapy Products, H1 2015 83

Number of Products by Top 10 Targets, H1 2015 84

Number of Products by Stage and Top 10 Targets, H1 2015 84

Number of Products by Top 10 Mechanism of Actions, H1 2015 88

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 88

Number of Products by Top 10 Routes of Administration, H1 2015 91

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 91

Number of Products by Top 10 Molecule Types, H1 2015 93

Number of Products by Stage and Top 10 Molecule Types, H1 2015 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Aprea AB

arGEN-X BV

Ariad Pharmaceuticals, Inc.

Array BioPharma Inc.

Astex Pharmaceuticals, Inc.

Bio-Path Holdings, Inc.

Biogenomics Limited

BioLineRx, Ltd.

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Cantargia AB

Celgene Corporation

Constellation Pharmaceuticals, Inc.

Daiichi Sankyo Company, Limited

Deciphera Pharmaceuticals, LLC

Eisai Co., Ltd.

EpiZyme, Inc.

Galena Biopharma, Inc.

Gamida Cell Ltd.

Hybrigenics S.A.

Ilyang Pharmaceutical Co., Ltd

Incyte Corporation

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Juno Therapeutics Inc.

JW Pharmaceutical Corporation

KaloBios Pharmaceuticals, Inc.

Karyopharm Therapeutics, Inc.

Lixte Biotechnology Holdings, Inc.

Mirna Therapeutics, Inc.

Natco Pharma Limited

Novartis AG

Onconova Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd.

OriBase Pharma

Otsuka Holdings Co., Ltd.

Pfizer Inc.

Pharma Mar, S.A.

PharmaEssentia Corporation

Selvita SA

Shenogen Pharma Group Ltd.

Stemline Therapeutics, Inc.

Sun Pharma Advanced Research Company Ltd.

Synta Pharmaceuticals Corp.

Threshold Pharmaceuticals, Inc.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutic Products under Development, Key Players in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline Overview, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com